Developer docs
API playgroundTry for free, no card

Search company profiles

Emocog

Full company profile

uuid0002jrn

Namestring
Emocog
Legal namestring
Emocog Inc.
Websiteurl
emocog.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Emocog is a South Korea-based digital therapeutics company founded in 2021 that develops software-based cognitive interventions for patients with mild cognitive impairment (MCI) and dementia risk, serving healthcare providers, hospital systems, and pharmaceutical partners across Korea, Germany, and preparation-stage U.S. operations. The company's flagship product Cogthera is a clinically validated digital therapeutic that continuously monitors patients' cognitive functions and delivers personalized cognitive training through a voice-based conversational interface with adaptive difficulty adjustment based on patient performance. Cogthera was designated as Korea's 35th Innovative Medical Device by the MFDS — the first cognitive intervention treatment software for MCI approved in the country — and is simultaneously pursuing Germany's DiGA fast-track reimbursement pathway through subsidiary Cogthera GmbH, with U.S. FDA pre-submission completed.

The company's product portfolio spans the full dementia care continuum: MemoryPick (기억콕콕) for mobile cognitive screening, Cogthera KR/DE for MCI treatment, PDT for Parkinson's disease diagnostic assistance, AlzVoice for voice-based memory and attention assessment, and Spectracheck (an IVD reagent). Through the 2023 acquisition of Happymind, Emocog extended into pediatric and adolescent learning disorder solutions including the CAT (Comprehensive Attention Test), CLT (Comprehensive Learning Test), NeuLearn English vocabulary app, and dyscalculia treatment programs. The 2024 acquisition of PL Group added CNS specialty drug distribution capability, creating vertical integration potential between pharmaceutical sales and digital therapeutic prescriptions. Strategic grand partnerships with Korea Eisai, Quanterix, Naver Cloud, NHN Waplat, and SK Telecom position the company within an integrated diagnostic-therapeutic-cloud ecosystem.

Emocog operates a B2B enterprise model with revenue generated primarily through healthcare provider prescriptions and institutional deployments of its regulated medical device products. The company sells through hospital channels (validated across 7 Korean university hospitals including Inje University Ilsan Paik Hospital, Ajou University Hospital, and Seoul National University Hospital), pursues regulatory-approved reimbursement pathways in Korea (MFDS) and Germany (DiGA), and leverages clinical conferences (CES, IFA, MEDICA, AD/PD) for market visibility. The company has raised approximately $27.2M across three funding rounds from Korean institutional investors including Naver, Kakao, Stonebridge Ventures, KB Investment, IBK, Shinhan Venture Investment, and Green Cross Holdings, and holds 23 related patents (9 registered, 14 filed) with 5 SCI-indexed publications backing its clinical claims.

Short descriptiontext

Emocog is a South Korea-based digital therapeutics company that develops and commercializes Cogthera, an MFDS-approved software for cognitive training in patients with mild cognitive impairment, serving hospitals, healthcare providers, and pharmaceutical partners across Korea and Germany.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, cognitive training software, dementia screening tools, mild cognitive impairment treatment, brain health platforms
Industry4 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
SECONDARYHLADACAJ
Memory Care Care Management & Navigation (Dementia Care Coordination)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Memory Care (Dementia/Alzheimer’s) Communities
SECONDARYHLACANAB
Prescription Digital Therapeutics (PDT)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Services for the Elderly and Persons with Disabilities62412
  • Nursing and Residential Care Facilities623
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Digital Therapeutics (Cognitive Healthcare Software)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cogthera Digital Therapeutics (Korea)
TypeSubscription Recurring
Description

Cogthera generates revenue as a regulated medical device prescribed by healthcare professionals. Approved by MFDS (Korea FDA) as the 35th Innovative Medical Device for mild cognitive impairment treatment.

emocog.com
2Cogthera DE (Germany DiGA)
TypeSubscription Recurring
Description

Digital therapeutic pursuing German DiGA (Digital treatments and medical applications) fast-track pathway through BfArM, enabling fast market entry with high insurance reimbursement rates.

emocog.com
3Cognitive Assessment Services
TypeSubscription Recurring
Description

MemoryPick and other cognitive assessment tools provided as screening services for dementia risk detection.

emocog.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1Cogthera
Description

Digital therapeutic device for mild cognitive impairment (MCI) providing personalized cognitive training. Available as Cogthera KR (Korea) and Cogthera DE (Germany/DiGA version). Government-approved and designated as 35th Innovative Medical Device in Korea.

emocog.com
+8 more records
Core offering1 text field

Emocog develops and markets digital therapeutics (DTx) for cognitive impairment and dementia care, anchored by Cogthera — a smartphone-based cognitive training software for patients aged 55-85 with mild cognitive impairment (MCI). The portfolio extends to mobile cognitive assessment (MemoryPick), voice-based verbal evaluation (AlzVoice), Parkinson's diagnostic support (PDT), and learning disability solutions (CAT, CLT, NeuLearn) acquired through Happymind. Products are deployed under healthcare professional supervision in Korea and pursued via Germany's DiGA fast-track pathway for reimbursement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Delays cognitive decline progression in MCI patients
+1 more record
Product overview1 text field

Emocog is a digital healthcare platform that develops and offers products across two main categories: dementia solutions and learning disorder solutions. The dementia ecosystem includes MemoryPick (mobile cognitive assessment), Cogthera KR/DE (digital therapeutics for MCI), PDT (Parkinson's diagnostic assistant), and AlzVoice (voice-based cognitive assessment). Following the acquisition of Happymind, Emocog expanded into learning disorder solutions including CAT (attention testing), CLT (learning disability screening), NeuLearn (English vocabulary learning), and a dyscalculia treatment program. The company operates a B2B model targeting healthcare providers, pharmaceutical partners, and educational institutions.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Collaboration at AD/PD 2026 conference to enhance diagnostic capabilities in U.S. and Korean markets, leveraging blood-based biomarkers and digital therapeutics to improve patient access to diagnosis and treatment while monitoring disease progression.

2Korea Eisai (Eisai Korea)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-07
Description

Korea Eisai, subsidiary of Japanese pharmaceutical company Eisai, partnered with Emocog as part of open innovation strategy in digital healthcare focused on dementia prevention, diagnosis, and management. Emocog is one of the startups collaborating with Eisai Korea, which also participated in government-led public-private partnership programs.

biz.chosun.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Signed MOU with Naver Cloud for cloud infrastructure and technology partnership.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Signed business agreement with NHN Waplat for technology collaboration and platform integration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Happymind is a learning disability solution company with high domestic market share for CAT (Comprehensive Attention Test). Emocog acquired Happymind to share development technology, know-how, and networks for rapid growth and business expansion.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Acquired Share & Service, a company developing respiratory rehabilitation digital therapeutics.

7PL Group
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Acquired PL Group, a CNS specialty drug distribution and sales company.

emocog.com
8Grand Partnership: Brightonix, Korea Eisai, DuchemBio, Neurophet, LabGenomics, PeopleBio, GCcare
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic grand partnerships formed for comprehensive digital healthcare ecosystem development in dementia care, combining diagnostics, therapeutics, and healthcare services.

emocog.com
Strategic tierSupportingTypeGTM or Marketing Partner
Description

German startup ecosystem hub where Cogthera GmbH is located; awarded Healthcare for Pharma prize.

Strategic tierSupportingTypeTechnology or Integration
Description

Technology partnership with Korean telecom provider for digital health solutions.

Strategic tierSupportingTypeOthers
Description

Membership in the Digital Therapeutics Alliance for industry standards and best practices.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Berlin-based DiGA-approved digital therapeutics company for mental health indications. Directly comparable DTx model targeting German reimbursement, providing a benchmark for regulatory and commercial execution.

TypeDirect peer
Description

German digital therapeutic for mild cognitive impairment, DiGA-listed and reimbursed. Closest direct competitor to Cogthera DE, competing for the same German payer channel and MCI patient population.

TypeDirect peer
Description

German digital health company offering a cognitive health app for memory monitoring and MCI support, often positioned alongside DiGA products. Direct competitor for patients and clinical partners in Germany.

TypeDirect peer
Description

US-based FDA-cleared digital cognitive assessment device for early detection of MCI and dementia. Comparable to Emocog's MemoryPick / AlzVoice on the screening side, with established US distribution.

TypeDirect peer
Description

US-based digital cognitive assessment platform with FDA Breakthrough Device designation for predicting MCI conversion to Alzheimer's. Competes with Emocog on digital biomarkers and early dementia detection.

TypeDirect peer
Description

US digital cognitive training company with extensive clinical evidence and major payer partnerships (Medicare). Closest comparator to Cogthera on the cognitive training side, with deeper US commercial footprint.

TypeDirect peer
Description

German consumer and clinical cognitive training app with millions of users, scientifically validated exercises. Adjacent competitor in the same cognitive-training category, though positioned more as a wellness product than a prescribed DTx.

TypeDirect peer
Description

German pioneer in DiGA-approved digital therapeutics with multiple listed products. Closely comparable business model for regulatory navigation, payer contracting, and evidence generation in the German market.

TypeDirect peer
Description

US digital health company offering cognitive assessment tools for dementia risk screening. Direct competitor to MemoryPick on the screening side, with established enterprise health partnerships.

TypeBroad incumbent
Description

Swiss-based neurotechnology company building digital therapeutics and assessment tools for neurological conditions including stroke, MCI, and Parkinson's. Broader portfolio than Emocog but overlaps in cognitive assessment and DTx for neurodegeneration.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emocog

Digital Therapeutics (Cognitive Healthcare Software)emocog.com

Emocog is a South Korea-based digital therapeutics company that develops and commercializes Cogthera, an MFDS-approved software for cognitive training in patients with mild cognitive impairment, serving hospitals, healthcare providers, and pharmaceutical partners across Korea and Germany.

What Emocog does

Emocog is a South Korea-based digital therapeutics company founded in 2021 that develops software-based cognitive interventions for patients with mild cognitive impairment (MCI) and dementia risk, serving healthcare providers, hospital systems, and pharmaceutical partners across Korea, Germany, and preparation-stage U.S. operations. The company's flagship product Cogthera is a clinically validated digital therapeutic that continuously monitors patients' cognitive functions and delivers personalized cognitive training through a voice-based conversational interface with adaptive difficulty adjustment based on patient performance. Cogthera was designated as Korea's 35th Innovative Medical Device by the MFDS — the first cognitive intervention treatment software for MCI approved in the country — and is simultaneously pursuing Germany's DiGA fast-track reimbursement pathway through subsidiary Cogthera GmbH, with U.S. FDA pre-submission completed.

The company's product portfolio spans the full dementia care continuum: MemoryPick (기억콕콕) for mobile cognitive screening, Cogthera KR/DE for MCI treatment, PDT for Parkinson's disease diagnostic assistance, AlzVoice for voice-based memory and attention assessment, and Spectracheck (an IVD reagent). Through the 2023 acquisition of Happymind, Emocog extended into pediatric and adolescent learning disorder solutions including the CAT (Comprehensive Attention Test), CLT (Comprehensive Learning Test), NeuLearn English vocabulary app, and dyscalculia treatment programs. The 2024 acquisition of PL Group added CNS specialty drug distribution capability, creating vertical integration potential between pharmaceutical sales and digital therapeutic prescriptions. Strategic grand partnerships with Korea Eisai, Quanterix, Naver Cloud, NHN Waplat, and SK Telecom position the company within an integrated diagnostic-therapeutic-cloud ecosystem.

Emocog operates a B2B enterprise model with revenue generated primarily through healthcare provider prescriptions and institutional deployments of its regulated medical device products. The company sells through hospital channels (validated across 7 Korean university hospitals including Inje University Ilsan Paik Hospital, Ajou University Hospital, and Seoul National University Hospital), pursues regulatory-approved reimbursement pathways in Korea (MFDS) and Germany (DiGA), and leverages clinical conferences (CES, IFA, MEDICA, AD/PD) for market visibility. The company has raised approximately $27.2M across three funding rounds from Korean institutional investors including Naver, Kakao, Stonebridge Ventures, KB Investment, IBK, Shinhan Venture Investment, and Green Cross Holdings, and holds 23 related patents (9 registered, 14 filed) with 5 SCI-indexed publications backing its clinical claims.

Emocog firmographics

Firmographics
Name
Emocog
Legal name
Emocog Inc.
Website
https://emocog.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Emocog is a South Korea-based digital therapeutics company that develops and commercializes Cogthera, an MFDS-approved software for cognitive training in patients with mild cognitive impairment, serving hospitals, healthcare providers, and pharmaceutical partners across Korea and Germany.
Ownership category
akta.pro rank

Emocog industry classification

Industry
Product category
Digital Therapeutics (Cognitive Healthcare Software)
NAICS
Services for the Elderly and Persons with Disabilities (62412), Nursing and Residential Care Facilities (623)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
SECONDARYHLADACAJ
Memory Care Care Management & Navigation (Dementia Care Coordination)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Memory Care (Dementia/Alzheimer’s) Communities
SECONDARYHLACANAB
Prescription Digital Therapeutics (PDT)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital therapeutics
  • Cognitive training software
  • Dementia screening tools
  • Mild cognitive impairment treatment
  • Brain health platforms

Where Emocog is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Emocog business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Cogthera Digital Therapeutics (Korea): Cogthera generates revenue as a regulated medical device prescribed by healthcare professionals. Approved by MFDS (Korea FDA) as the 35th Innovative Medical Device for mild cognitive impairment treatment.
  2. Cogthera DE (Germany DiGA): Digital therapeutic pursuing German DiGA (Digital treatments and medical applications) fast-track pathway through BfArM, enabling fast market entry with high insurance reimbursement rates.
  3. Cognitive Assessment Services: MemoryPick and other cognitive assessment tools provided as screening services for dementia risk detection.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Emocog product offering

Product offering

Core offering

Emocog develops and markets digital therapeutics (DTx) for cognitive impairment and dementia care, anchored by Cogthera — a smartphone-based cognitive training software for patients aged 55-85 with mild cognitive impairment (MCI). The portfolio extends to mobile cognitive assessment (MemoryPick), voice-based verbal evaluation (AlzVoice), Parkinson's diagnostic support (PDT), and learning disability solutions (CAT, CLT, NeuLearn) acquired through Happymind. Products are deployed under healthcare professional supervision in Korea and pursued via Germany's DiGA fast-track pathway for reimbursement.

Product overview

Emocog is a digital healthcare platform that develops and offers products across two main categories: dementia solutions and learning disorder solutions. The dementia ecosystem includes MemoryPick (mobile cognitive assessment), Cogthera KR/DE (digital therapeutics for MCI), PDT (Parkinson's diagnostic assistant), and AlzVoice (voice-based cognitive assessment). Following the acquisition of Happymind, Emocog expanded into learning disorder solutions including CAT (attention testing), CLT (learning disability screening), NeuLearn (English vocabulary learning), and a dyscalculia treatment program. The company operates a B2B model targeting healthcare providers, pharmaceutical partners, and educational institutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Cogthera: Digital therapeutic device for mild cognitive impairment (MCI) providing personalized cognitive training. Available as Cogthera KR (Korea) and Cogthera DE (Germany/DiGA version). Government-approved and designated as 35th Innovative Medical Device in Korea.
  • MemoryPick (기억콕콕)
  • PDT
  • AlzVoice
  • CAT (Comprehensive Attention Test)
  • CLT (Comprehensive Learning Test)
  • NeuLearn
  • sCAT
  • Spectracheck

Quantifiable outcome

  • Delays cognitive decline progression in MCI patients
  • +1 more outcomes

Companies that use Emocog

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Emocog technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Emocog partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and supporting.

  • QuanterixcoreStrategic or Co-development Partner · 23 March 2026Collaboration at AD/PD 2026 conference to enhance diagnostic capabilities in U.S. and Korean markets, leveraging blood-based biomarkers and digital therapeutics to improve patient access to diagnosis and treatment while monitoring disease progression.
  • Korea Eisai (Eisai Korea)coreStrategic or Co-development Partner · 7 December 2025Korea Eisai, subsidiary of Japanese pharmaceutical company Eisai, partnered with Emocog as part of open innovation strategy in digital healthcare focused on dementia prevention, diagnosis, and management. Emocog is one of the startups collaborating with Eisai Korea, which also participated in government-led public-private partnership programs.
  • Naver CloudmajorStrategic or Co-development PartnerSigned MOU with Naver Cloud for cloud infrastructure and technology partnership.
  • NHN WaplatmajorStrategic or Co-development PartnerSigned business agreement with NHN Waplat for technology collaboration and platform integration.
  • HappymindcoreStrategic or Co-development PartnerHappymind is a learning disability solution company with high domestic market share for CAT (Comprehensive Attention Test). Emocog acquired Happymind to share development technology, know-how, and networks for rapid growth and business expansion.
  • Share & ServicesupportingStrategic or Co-development PartnerAcquired Share & Service, a company developing respiratory rehabilitation digital therapeutics.
  • PL GroupsupportingStrategic or Co-development PartnerAcquired PL Group, a CNS specialty drug distribution and sales company.
  • Grand Partnership: Brightonix, Korea Eisai, DuchemBio, Neurophet, LabGenomics, PeopleBio, GCcarecoreStrategic or Co-development PartnerStrategic grand partnerships formed for comprehensive digital healthcare ecosystem development in dementia care, combining diagnostics, therapeutics, and healthcare services.
  • 5-HT Digital HubsupportingGTM or Marketing PartnerGerman startup ecosystem hub where Cogthera GmbH is located; awarded Healthcare for Pharma prize.
  • SK TelecomsupportingTechnology or IntegrationTechnology partnership with Korean telecom provider for digital health solutions.
  • Digital Therapeutics Alliance (DTA)supportingOthersMembership in the Digital Therapeutics Alliance for industry standards and best practices.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Emocog competitors and assessment

Company assessment

Direct peers

  • Selfapy: Berlin-based DiGA-approved digital therapeutics company for mental health indications. Directly comparable DTx model targeting German reimbursement, providing a benchmark for regulatory and commercial execution.
  • Memodio: German digital therapeutic for mild cognitive impairment, DiGA-listed and reimbursed. Closest direct competitor to Cogthera DE, competing for the same German payer channel and MCI patient population.
  • neotiv: German digital health company offering a cognitive health app for memory monitoring and MCI support, often positioned alongside DiGA products. Direct competitor for patients and clinical partners in Germany.
  • Cognivue: US-based FDA-cleared digital cognitive assessment device for early detection of MCI and dementia. Comparable to Emocog's MemoryPick / AlzVoice on the screening side, with established US distribution.
  • Altoida: US-based digital cognitive assessment platform with FDA Breakthrough Device designation for predicting MCI conversion to Alzheimer's. Competes with Emocog on digital biomarkers and early dementia detection.
  • Posit Science (BrainHQ): US digital cognitive training company with extensive clinical evidence and major payer partnerships (Medicare). Closest comparator to Cogthera on the cognitive training side, with deeper US commercial footprint.
  • NeuroNation: German consumer and clinical cognitive training app with millions of users, scientifically validated exercises. Adjacent competitor in the same cognitive-training category, though positioned more as a wellness product than a prescribed DTx.
  • GAIA AG: German pioneer in DiGA-approved digital therapeutics with multiple listed products. Closely comparable business model for regulatory navigation, payer contracting, and evidence generation in the German market.
  • Neurotrack Technologies: US digital health company offering cognitive assessment tools for dementia risk screening. Direct competitor to MemoryPick on the screening side, with established enterprise health partnerships.

Broad incumbents

  • MindMaze: Swiss-based neurotechnology company building digital therapeutics and assessment tools for neurological conditions including stroke, MCI, and Parkinson's. Broader portfolio than Emocog but overlaps in cognitive assessment and DTx for neurodegeneration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Emocog compliance and trust

Trust signal

Compliance5 records

Emocog financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emocog leadership team

Management profile

Number of profiles

Profiles8 records

Emocog subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Emocog funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emocog M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emocog

What does Emocog do?

Emocog develops and markets digital therapeutics (DTx) for cognitive impairment and dementia care, anchored by Cogthera — a smartphone-based cognitive training software for patients aged 55-85 with mild cognitive impairment (MCI). The portfolio extends to mobile cognitive assessment (MemoryPick), voice-based verbal evaluation (AlzVoice), Parkinson's diagnostic support (PDT), and learning disability solutions (CAT, CLT, NeuLearn) acquired through Happymind. Products are deployed under healthcare professional supervision in Korea and pursued via Germany's DiGA fast-track pathway for reimbursement.

Is Emocog a public or private company?

Emocog is a private company. It is classified as venture growth investor backed and is currently operating.

When was Emocog founded?

Emocog was founded in 2021. It employs 11 to 50 people.

Where is Emocog based?

Emocog is headquartered in Seoul, South Korea, in the Asia region.

How does Emocog make money?

Three revenue lines are on record. Cogthera Digital Therapeutics (Korea) is the primary driver. The others are cogthera DE (Germany DiGA) and cognitive Assessment Services.

Who are Emocog's main competitors?

Direct peers on record are Selfapy, Memodio, neotiv, Cognivue, Altoida, Posit Science (BrainHQ), NeuroNation, GAIA AG and Neurotrack Technologies. MindMaze is listed as a broad incumbent.

Does Emocog have an API?

No public API is recorded for Emocog.

What industry is Emocog in?

Emocog's product category is Digital Therapeutics (Cognitive Healthcare Software). Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLADALAF, Dementia/Alzheimer’s Care Management & Behavioral Support. Its NAICS code is 62412 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartuptodayImocog has signed a domestic exclusive sales and commercialization contract for 'Cogtera∙Cogscreen' with Daewoong Pharmaceutical.Emocog signed an exclusive domestic licensing and commercialization contract with Daewoong Pharmaceutical for its digital therapeutic Cogtera and screening tool Cogscreener. Daewoong will distribute nationwide for three years, while Emocog handles software updates and regulatory approvals. The companies plan to start field sales on October 1, targeting medical institutions.KBR'Digital cognitive training finds bigger role as Alzheimer’s treatment shifts earlier'Professor Kang Dong-woo of the Catholic University of Korea Seoul St. Mary’s Hospital advocates for shifting Alzheimer's treatment to earlier stages, specifically mild cognitive impairment (MCI), by combining disease-modifying therapies with digital cognitive training. He highlights Emocog's Cogthera as a key digital therapeutic that adapts difficulty based on patient performance and allows clinicians to monitor adherence and progress. This approach aims to strengthen cognitive reserve and slow disease progression, addressing limitations of conventional in-person training.Healthcare IT NewsLatest hospital digitisation in Korea, Hong KongInje University Ilsan Paik Hospital in South Korea has launched Cogthera, a government-approved smartphone-based digital therapeutic for cognitive training in patients aged 55-85 with mild cognitive impairment, developed by local company Emocog and tested across seven university hospitals. Hong Kong's Hospital Authority will extend digitally signed electronic certificates to maternity and sick leave from April 24, replacing paper certificates with encrypted QR code verification through the HA Go mobile app. Ajou University Hospital in South Korea has upgraded its online medical record issuance system and introduced mobile questionnaire services as part of broader digital patient service expansion.KBR[AD/PD 2026] Quanterix, Emocog push blood tests, digital tools into Alzheimer’s mainstreamIndustry leaders Quanterix and Emocog showcased their collaborative diagnostic solutions for Alzheimer's disease at the AD/PD 2026 conference in Copenhagen, highlighting ultra-sensitive blood-based biomarkers on Quanterix's Simoa platform and Emocog's multi-modal Cogcheck digital platform that integrates blood tests, imaging, and cognitive assessments. The companies are strategically targeting Korea to transition the Simoa technology from research use to formal in vitro diagnostic approval within the year, with Emocog planning to supply tests at affordable prices even before national insurance coverage. Emocog researchers also presented findings demonstrating that combining blood biomarkers with acoustic and semantic features from speech tests significantly improves predictive accuracy for disease monitoring, and the company is collaborating with Naver to integrate voice-based dementia screening into the Clova CareCall system.Life Science Company NewsKorea marks milestone for blood-based Alzheimer’s diagnostics ecosystemKorea has entered into an exclusive distribution agreement with Quanterix Corporation and Emocog Inc. for the Simoa® blood-based Alzheimer’s diagnostic technology. This milestone introduces the platform into Korea as a formally authorized IVD device, supporting the development of Korea’s blood-based Alzheimer’s diagnostics ecosystem.KBREmocog brings Quanterix’s ultra-sensitive Alzheimer’s blood test platform to KoreaEmocog announced an exclusive agreement with U.S.-based Quanterix Corp. to introduce the Simoa ultra-high-sensitivity protein analysis platform and blood-based diagnostic reagents for Alzheimer's screening in Korea, marking the first instance of the Simoa platform entering Korea's in vitro diagnostic (IVD) framework rather than for research use only. Emocog completed import registration of the Simoa HD-X analyzer as a Class I IVD device with Korea's Ministry of Food and Drug Safety at the end of October and is preparing for domestic clinical trials and approval procedures for diagnostic reagents including the pTau217 biomarker. The companies aim to build an integrated cognitive health ecosystem combining digital assessment, cognitive intervention, and blood-based diagnostics to strengthen Korea's dementia response capabilities.ChosunbizEmocog brings Simoa blood dementia test to Korea through exclusive Quanterix dealEmocog, a South Korean digital healthcare company, has signed an exclusive domestic supply contract with Lucent Diagnostics, the clinical diagnostics brand of U.S. biotech Quanterix, to introduce the Simoa ultra-high-sensitivity protein analysis platform and blood-based in vitro diagnostic reagents to Korea for the first time as a formal IVD system. The Simoa HD-X analyzer has been filed with Korea's Ministry of Food and Drug Safety as a Class 1 IVD device, and Emocog is preparing domestic clinical trials and approvals for key diagnostic reagents including pTau217, a core blood biomarker for Alzheimer's disease, which would enable early Alzheimer's risk assessment from a single blood draw upon approval. The partnership creates a full-cycle dementia Digital Healthcare ecosystem combining digital cognitive assessment, mobile-based cognitive therapy, and blood-based Alzheimer's screening.ChosunbizKorea Eisai partners with startups to raise patient experience from prevention to managementKorea Eisai, the Korean subsidiary of Japanese pharmaceutical company Eisai, is strengthening its open innovation strategy by partnering with domestic startups and small-to-mid-sized enterprises in digital healthcare focused on dementia prevention, diagnosis, and management. The company has collaborated with startups including NeuroXti, Emocog, and Kriple, which developed solutions for Alzheimer's diagnosis, mild cognitive impairment digital therapeutics, and cognitive training services respectively. Korea Eisai has also participated in government-led public-private partnership programs and plans to expand mid-to-long-term proof-of-concept initiatives in digital health and AI while building a strategic collaboration roadmap with Korean startups.KBR'Korean DTx industry crossing 'death valley' seeks post-approval survival'Korea's digital therapeutic (DTx) industry has secured regulatory approval for seven products from the Ministry of Food and Drug Safety, but faces a critical 'death valley' phase characterized by low clinical prescription rates due to regulatory barriers, limited distribution channels dominated by pharmaceutical companies, and insufficient awareness among healthcare professionals and patients. EverTri CEO Shin Jae-yong explains that developers struggle with cumbersome prescription processes and difficulties in establishing distribution partnerships with tertiary general hospitals, prompting the industry to explore telemedicine platforms and integration with national health programs as potential solutions. The market is expected to become more competitive as DTx development expands into indications like ADHD and age-related conditions, with companies like Emocog pursuing platform consolidation strategies.